Understanding Alliance Discrepancies in Youth Therapy: A Case Study of Rupture and Repair in CBT.

Psychother ResOct 20, 2025 (epub)
Case ReportPsychiatry

Zhongze Ren, Tanya Lecchi, Antonella Cirasola

✦ AI-curated · Sources linked

Case in brief

A case study examined cognitive behavioral therapy for an adolescent with depression, using session recordings, alliance ratings, and post-therapy interviews with the adolescent and therapist. The adolescent consistently rated the therapeutic alliance more strongly than the therapist did. Review of sessions and interviews suggested that the adolescent’s high ratings reflected excessive compliance that obscured subtle withdrawal ruptures. The therapist recognized this dynamic and worked to address the ruptures; most were repaired. At the end of therapy, both described the relationship positively.

What made this case unusual

The adolescent’s consistently high alliance ratings masked a compliance-driven pseudo-alliance, while the therapist’s lower ratings reflected awareness of subtle withdrawal ruptures.

Diagnostic / clinical pearl

High alliance ratings from a young client do not necessarily rule out rupture: excessive compliance may conceal withdrawal, so ratings should be considered alongside observed interactions and the client’s account.

Source

Published in Psychother Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.